As UK Patent Office Upholds Enigma's PCR Patents, Biogene Exec Says Dispute 'Far from Closed' | GenomeWeb

This article has been updated from a previous version to clarify the identities of the parties in the original lawsuit.

By Ben Butkus

The UK Intellectual Property Office has recently rejected a revocation action brought by an executive from molecular biology firm Biogene against three PCR patents owned by the UK's Defence Science and Technology Laboratory and exclusively licensed to Enigma Diagnostics, according to recently filed court documents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."